Gene · 10818
FRS2: fibroblast growth factor receptor substrate 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. FRS2: fibroblast growth factor receptor substrate 2. Genes, record 10818. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10818
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q8WU20 | Fibroblast growth factor receptor substrate 2 | 508 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents28
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 11554 | Q8WU20 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 11554 | Q8WU20 | Espacenet |
| JP 2023123507 A | 2023-09-05 | 136 | Q8WU20 | Espacenet |
| JP 2022541456 A | 2022-09-26 | 11 | Q8WU20 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 31968 | Q8WU20 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 31970 | Q8WU20 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 31978 | Q8WU20 | Espacenet |
| JP 2022537339 A | 2022-08-25 | 5 | Q8WU20 | Espacenet |
| KR 1020220075306 A | 2022-06-08 | 5 | Q8WU20 | Espacenet |
| US 11326167 B2 | 2022-05-10 | 23 | Q8WU20 | Espacenet |
1 to 10 of 28
See all 28 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,029
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | FRS2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 25 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 15 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 8 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 5 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 5 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 4 | 2025 |
| R01EY017061 | Signaling Mechanisms of Lens Development | 4 | 2025 |
| K12CA090628 | Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic | 3 | 2025 |
| P30CA013148 | Comprehensive Cancer Center Support Grant | 3 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,029Source NIH's project files
See all 1,029 nih grantsPapers1,537
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Correction: Mechanistic insights into cannabidiol-mediated TrkB activation via FRS2 interaction in attenuating Alzheimer's disease pathology and cognitive impairment. | Mol Psychiatry | 2026 | 42687000 | PubTator, text mining | PubMed |
| Tanshinone IIA attenuates myocardial ischemia by targeting FGFR1 residue Gln284 for allosteric modulation and subsequent autophagy inhibition. | Phytomedicine | 2026 | 42542063 | PubTator, text mining | PubMed |
| AI-Driven discovery and experimental validation of covalent FGFR4 inhibitors for hepatocellular carcinoma. | J Transl Med | 2026 | 42482266 | PubTator, text mining | PubMed |
| Fibroblast growth factor receptor substrate 2 interactome mapping reveals novel candidate interactors associated with migration and invasion. | Cell Commun Signal | 2026 | 42169144 | PubTator, text mining | PubMed |
| Selection and Optimization of a High-Affinity FGFR4 Aptamer that Blocks FGF19-FGFR4 Signaling. | Anal Chem | 2026 | 42159546 | PubTator, text mining | PubMed |
| Fibroblast growth factor 10 attenuates advanced liver fibrosis through hepatocyte fibroblast growth factor receptor 2 signalling. | Clin Transl Med | 2026 | 42117407 | PubTator, text mining | PubMed |
| Novel transcriptomic alterations in poorly differentiated endometrial carcinomas: evidence from South African women. | Front Oncol | 2026 | 41952686 | PubTator, text mining | PubMed |
| 2H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as novel selective fibroblast growth factor receptor 2 (FGFR2) inhibitors. | J Enzyme Inhib Med Chem | 2026 | 41910341 | PubTator, text mining | PubMed |
| FGF family in health and disease. | Mol Biomed | 2026 | 41832306 | PubTator, text mining | PubMed |
| Functional insights into the biosynthesis of antifungal mandimycin. | Pest Manag Sci | 2026 | 41821138 | PubTator, text mining | PubMed |
1 to 10 of 1,537
See all 1,537 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/10818
GET https://conductscience.org/api/genes/v1/10818/patents?page=2